Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, ...

The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis, psoriasis, ...

The firm will assess irpagratinib plus best supportive care in patients with FGF19-overexpressing advanced liver cancer.

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

In clinical trials, the tyrosine kinase inhibitor demonstrated a confirmed overall response rate of up to 90 percent and brain-penetrant efficacy.

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for ...

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL ...

This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for ...